Skip to main content

Table 1 Characteristics of systemic sclerosis patients (n = 40)

From: Nifedipine decreases sVCAM-1 concentrations and oxidative stress in systemic sclerosis but does not affect the concentrations of vascular endothelial growth factor or its soluble receptor 1

Characteristic Value
Cutaneous form of the disease: limited / diffuse 23 (57) / 17 (43)
Digital pitting scars 6 (15)
Pulmonary arterial pressure (PAP)  
   mmHg [mean ± SD (range)] 33 ± 6 (21–48)
   >40 mmHg 6 (15)
Pulmonary fibrosis (computed tomography scan) 16 (40)
Forced vital capacity below 75% of normal values 9 (23)
Decreased carbon monoxide diffusing capacity (DLCO/Hb <75%) 16 (40)
Left ventricular ejection fraction (%) (mean ± SD%) 62 ± 8
Antinuclear antibodies ≥1/160 38 (92)
Anti-topoisomerase I antibodies/anti-centromere antibodies 12/7
Creatininaemia (μmol) (mean ± SD) 79 ± 13
Erythrocyte sedimentation rate (mm/1st hour) (mean ± SD) 21 ± 18
C-reactive protein (mg/l) (mean ± SD) 11 ± 16
Ongoing low-dose prednisone (no. patients) (mean mg/day ± SD) 14 (7.4 ± 2)
Ongoing angiotensin-converting enzyme inhibitors (no. patients) 7
Ongoing low-dose aspirin therapy (no. patients) 25
  1. Values are number (%) of patients unless otherwise indicated. DLCO, carbon monoxide diffusion in the lung; Hb, hemoglobin.